57.81MMarket Cap-2460P/E (TTM)
2.330High2.180Low64.05KVolume2.250Open2.210Pre Close143.68KTurnover0.46%Turnover RatioLossP/E (Static)26.40MShares7.75052wk High3.53P/B30.85MFloat Cap1.40052wk Low--Dividend TTM14.09MShs Float8.680Historical High--Div YieldTTM6.79%Amplitude0.680Historical Low2.243Avg Price1Lot Size
Immix Biopharma Stock Forum
News
MT Newswires· 1 min ago
Immix Biopharma (IMMX) Thursday said it is on track to dose first patients with relapsed or refractory AL Amyloidosis with its CAR-T NXC-201 therapy candidate by mid-2024 after scheduling initiation visits at US testing locations this month and May.
The open-label, phase 1b dose-expansion trial is expected to enroll around 40 patients with adequate cardia...
NEWS
Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
LOS ANGELES, April 15, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and other autoimmune diseases, today announced that updated...
Update
Nice
5 MINUTES AGO, 4:45 PM EST
VIA GLOBENEWSWIRE
Update
LOS ANGELES, February 5, 2024 — Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, today announced that it has priced an underwritten public offering of 5,535,055 shares of its common stock at an offering price of $2.71 per share of common stock. ImmixBio has granted the underwriters a 30-day option to purchase up to 783,970 additional sha...
2 week recovery
News!
Benzinga· 2 mins ago
News
Benzinga· 4 mins ago
100% overall response rate observed in relapsed/refractory AL Amyloidosis patients with median 6 lines of prior therapy
Updated results will be communicated at the presentation time December 10, 2023
Watching this
$Immix Biopharma(IMMX.US)$
No comment yet